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Summary
Genome-wide association studies have identified loci underlying human diseases, but the causal 
nucleotide changes and mechanisms remain largely unknown. Here we developed a fine-mapping 
algorithm to identify candidate causal variants for 21 autoimmune diseases from genotyping data. 
We integrated these predictions with transcription and cis-regulatory element annotations, derived 
by mapping RNA and chromatin in primary immune cells, including resting and stimulated CD4+ 
T-cell subsets, regulatory T-cells, CD8+ T-cells, B-cells, and monocytes. We find that ~90% of 
causal variants are noncoding, with ~60% mapping to immune-cell enhancers, many of which gain 
histone acetylation and transcribe enhancer-associated RNA upon immune stimulation. Causal 
variants tend to occur near binding sites for master regulators of immune differentiation and 
stimulus-dependent gene activation, but only 10–20% directly alter recognizable transcription 
factor binding motifs. Rather, most noncoding risk variants, including those that alter gene 
expression, affect non-canonical sequence determinants not well-explained by current gene 
regulatory models.
Introduction
Genome-wide association studies (GWAS) have revolutionized the study of complex human 
traits by identifying thousands of genetic loci that contribute susceptibility for a diverse set 
of diseases1,2. However, progress towards understanding disease mechanisms has been 
limited by difficulty in assigning molecular function to the vast majority of GWAS hits that 
do not affect protein-coding sequence. Efforts to decipher biological consequences of 
noncoding variation face two major challenges. First, due to haplotype structure, GWAS 
tend to nominate large clusters of single nucleotide polymorphisms (SNPs) in linkage 
disequilibrium (LD), making it difficult to distinguish causal SNPs from neutral variants in 
linkage. Second, even assuming the causal variant can be identified, interpretation is limited 
by incomplete knowledge of noncoding regulatory elements, their mechanisms of action, 
and the cellular states and processes in which they function.
Inflammatory autoimmune diseases, which reflect complex interactions between genetic 
variation and environment, are important systems for genetic investigation of human 
disease3. They share a substantial degree of immunopathology, with increased activity of 
auto-reactive CD4+ T-cells secreting inflammatory cytokines and loss of regulatory T-cell 
(Treg) function4. A critical role for B-cells in certain diseases has also been revealed with the 
therapeutic efficacy of anti-CD20 antibodies5. Immune homeostasis depends on a balance of 
CD4+ pro-inflammatory (Th1, Th2, Th17) cells and FOXP3+ suppressive Tregs, each of 
which expresses distinct cytokines and surface molecules6. Each cell type is controlled by a 
unique set of master transcription factors (TFs) that directly shape cell-type specific gene 
expression programs, which include genes implicated in autoimmune diseases7–9. Immune 
subsets also have characteristic cis-regulatory landscapes, including distinct sets of 
enhancers that may be distinguished by their chromatin states9–13 and associated enhancer 
RNAs (eRNA)14. Familial clustering of different autoimmune diseases suggests that 
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heritable factors underlie common disease pathways, although disparate clinical 
presentations and paradoxical effects of drugs in different diseases support key 
distinctions15.
GWAS have discovered hundreds of risk loci for autoimmunity15. While most risk variants 
have subtle effects on disease susceptibility, they provide unbiased support for possible 
etiological pathways, including antigen presentation, cytokine signaling, and NFκB 
transcriptional regulation15. The associated loci are enriched for immune cell-specific 
enhancers10,16,17 and expansive enhancer clusters18,19, termed ‘super-enhancers’, 
implicating gene regulatory processes in disease etiology. However, as is typical of GWAS, 
the implicated loci comprise multiple variants in LD and rarely alter protein coding 
sequence, which complicates their interpretation.
Here, we integrated genetic and epigenetic fine-mapping to identify causal variants in 
autoimmune disease-associated loci and explore their functions. Based on dense genotyping 
data20, we developed a novel algorithm to predict for each individual variant associated with 
21 autoimmune diseases, the likelihood that it represents a causal variant. In parallel, we 
generated cis-regulatory element maps for a spectrum of immune cell types. Remarkably, 
~60% of likely causal variants map to enhancer-like elements, with preferential 
correspondence to stimulus-dependent CD4+ T-cell enhancers that respond to immune 
activation by increasing histone acetylation and transcribing noncoding RNAs. Although 
these enhancers frequently reside within extended clusters, their distinct regulatory patterns 
and phenotypic associations suggest they represent independent functional units. Causal 
SNPs are enriched near binding sites for immune-related TFs, but rarely alter their cognate 
motifs. Our study provides a unique resource for the study of autoimmunity, links causal 
disease variants with high probability to context-specific immune enhancers, and suggests 
that most non-coding causal variants act by altering non-canonical regulatory sequence 
rather than recognizable consensus TF motifs.
Fine-mapped Genetic Architecture of Disease
To explore the genetic architecture underlying common diseases, we first collected 39 well-
powered GWAS studies (Methods). Clustering of diseases and traits based on their shared 
genetic loci revealed groups of phenotypes with related clinical features (Fig 1A). This 
highlighted a large cluster of immune-mediated diseases forming a complex network of 
shared genetic loci; on average, 69% of the associated loci for each disease were shared with 
other autoimmune diseases, although no two diseases shared more than 38% of their loci.
We focused subsequent analysis on autoimmune diseases, reasoning that recent dense 
genotyping data combined with emerging approaches for profiling epigenomes of 
specialized immune cells would provide an opportunity to identify and characterize the 
specific causal SNPs. Prior studies that have integrated GWAS with epigenomic features 
focused on lead SNPs or multiple associated SNPs within a locus, of which only a small 
minority reflects causal variants10,16–19,21. Although these studies demonstrated enrichments 
within enhancer-like regulatory elements, they could not with any degree of certainty 
pinpoint the specific elements or processes affected by the causal variants. To overcome this 
limitation, we leveraged dense genotyping data to refine a statistical model for predicting 
Farh et al. Page 3
Nature. Author manuscript; available in PMC 2015 August 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
causal SNPs from genetic data alone. Rare recombination events within haplotypes can 
provide information on the identity of the causal SNP, provided sufficient genotyping 
density and sample size. We therefore examined a cohort of 14,277 cases with multiple 
sclerosis (MS) and 23,605 healthy controls genotyped using the Immunochip, which 
comprehensively covers 1000 Genomes Project SNPs22 within 186 loci associated with 
autoimmunity20. We developed an algorithm, Probabilistic Identification of Causal SNPs 
(PICS), that estimates the probability that an individual SNP is a causal variant given the 
haplotype structure and observed pattern of association at the locus (Methods, Extended 
Data Figs 1–4).
The IFI30 locus (Fig 1B–C) presents an illustrative example of the LD problem and the 
PICS strategy. The most strongly associated SNP at the locus is rs11554159 (R76Q, G>A; 
minor allele is protective), a missense variant in IFI30, a lysosomal enzyme that processes 
antigens for MHC presentation23. Although dozens of SNPs at the locus are significantly 
associated with disease, the association for each additional SNP follows a linear relationship 
with its linkage to rs11554159/R76Q, suggesting they owe their association solely to linkage 
with this causal variant. We used permutation to estimate the posterior probability for each 
SNP in the locus to be the causal variant, given the observed patterns of association. 
Interestingly, prior GWAS studies24 had attributed the signal at this locus to a missense 
variant in a neighboring gene, MPV17L2 (rs874628, r2 = 0.9 to R76Q), with no known 
immune function. However, we find that the R76Q variant is ~10 times more likely than 
rs874628 to be the causal SNP and three times more likely than the next closest SNP (a 
noncoding variant), providing compelling evidence that the IFI30 missense variant is the 
causal variant in the locus.
We next generalized PICS to analyze 21 autoimmune diseases, using Immunochip data 
when they were available or imputation to the 1000 Genomes Project22 when they were not 
(Methods; Supplementary Table S1). We mapped 636 autoimmune GWAS signals to 4950 
candidate causal SNPs (mean probability of representing the causal variant responsible for 
the GWAS signal: ~10%). PICS indicates that index SNPs reported in the GWAS catalog 
have on average only a 5% chance of representing a causal SNP. Rather, GWAS catalog 
index SNPs are typically some distance from the PICS lead SNP (median 14 kb), and many 
are not in tight LD (Fig 1D, Extended Data Figure 5). PICS identified a single most likely 
causal SNP (>75% probability) at 12% of loci linked to autoimmunity. However, most 
GWAS signals could not be fully resolved due to LD and thus contain several candidate 
causal SNPs (Fig 1E).
To confirm the functional significance of fine-mapped SNPs, we compared PICS SNPs 
against a strict background of random SNPs drawn from the same loci. Candidate causal 
SNPs derived by PICS were strongly enriched for protein-coding (missense, nonsense, 
frameshift) changes, which account for 14% of the predicted causal variants compared to 
just 4% of the random SNPs. Modest enrichments over the locus background were also 
observed for synonymous substitutions (5%), 3′ UTRs (3%), and splice junctions (0.2%) 
(Fig 1F). Although these results support the efficacy of PICS for identifying causal variants, 
~90% of GWAS hits for autoimmune diseases remain unexplained by protein-coding 
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variants. Candidate causal SNPs and the PICS algorithm are available through an 
accompanying online portal (www.broadinstitute.org/pubs/finemapping).
Causal Autoimmunity Variants Map to Immune Cell-Specific Enhancers
To investigate the functions of predicted causal noncoding variants, we generated a resource 
of epigenomic maps for specialized immune subsets (Extended Data Figure 6). We 
examined primary human CD4+ T-cell populations from pooled healthy donor blood, 
including FOXP3+CD25highCD127low/−regulatory (Tregs), CD25−CD45RA+CD45RO− 
naïve (Tnaïve) and CD25−CD45RA−CD45RO+ memory (Tmem) T-cells, and ex vivo phorbol 
myristate acetate (PMA)/ionomycin stimulated CD4+ T-cells separated into IL-17-positive 
(CD25−IL17A+; Th17) and IL-17-negative (CD25−IL17A−; Thstim) subsets. We also 
examined naïve and memory CD8+ T-cells, B-cell centroblasts from pediatric tonsils 
(CD20+CD10+CXCR4+CD44−), and peripheral blood B-cells (CD20+) and monocytes 
(CD14+). We mapped six histone modifications by chromatin immunoprecipitation-
sequencing (ChIP-seq) for all ten populations, and performed RNA-sequencing (RNA-seq) 
for each CD4+ T-cell population. We also incorporated data for B-lymphoblastoid cells17, 
Th0, Th1 and Th2 stimulated T-cells10, and non-immune cells from the NIH Epigenomics 
Project25 and ENCODE26, for a total of 56 cell types.
For each cell type, we computed a genome-wide map of cis-regulatory elements based on 
H3 lysine 27 acetylation (H3K27ac), a marker of active promoters and enhancers12. We then 
clustered cell types based on these cis-regulatory element patterns (Extended Data Figure 7). 
Fine distinctions could be drawn between CD4+ T-cell subsets based on quantitative 
differences in H3K27ac at thousands of putative enhancers (Fig 2A). These cell type-
specific H3K27ac patterns correlate with the expression of proximal genes. In contrast, H3 
lysine 4 mono-methylation (H3K4me1) was more uniform across subsets, consistent with its 
association to open or ‘poised’ sites shared between related cell types12.
Mapping of autoimmune disease PICS SNPs to these regulatory annotations revealed 
enrichment in B-cell and T-cell enhancers (Fig 2A). A disproportionate correspondence to 
enhancers activated upon T-cell stimulation prompted us to examine such elements more 
closely. Substantial subsets of immune-specific enhancers markedly increase their H3K27ac 
signals upon ex vivo stimulation, often in conjunction with noncoding eRNA transcription, 
and induction of proximal genes (Figs 2A–B). Compared to naïve T-cells, enhancers in 
stimulated T-cells are strongly enriched for consensus motifs recognized by AP-1 TFs, 
master regulators of cellular responses to stimuli. PICS SNPs are strongly enriched within 
stimulus-dependent enhancers (p<10−20 for combined PMA/Iono; p<10−11 for combined 
CD3/CD28), while enhancers preferentially marked in unstimulated T-cells show no 
enrichment for causal variants. Candidate causal SNPs were further enriched in T-cell 
enhancers that produce noncoding RNAs upon stimulation (1.6-fold; p<0.01).
The association of candidate causal SNPs to immune enhancers increases with PICS 
probability score (Fig 2C). We estimate that immune enhancers overall account for ~60% of 
candidate causal SNPs, whereas promoters account for another ~8% of these variants 
(Extended Data Figure 7). When we compared these statistics against GWAS catalog SNPs, 
which were the focus of prior studies linking GWAS to regulatory annotations10,16–19,21, we 
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found that the subset of associated SNPs that do not correspond to a PICS SNP fail to show 
any enrichment for T-cell enhancers, relative to locus controls (Figs 2D–E). These data 
support the efficacy of PICS and link likely causal autoimmune disease variants to specific 
enhancers activated upon immune stimulation.
Cell-Type Specific Signatures of Complex Diseases
Along with the 21 autoimmune diseases, we predicted causal SNPs for 18 other traits and 
diseases (Methods). Comparing SNP locations with chromatin maps for 56 cell types 
revealed the cell type-specificities of cis-regulatory elements that coincide with PICS SNPs, 
thus predicting cell types contributing to each phenotype (Fig 3). The patterns are more 
informative than the expression patterns of genes targeted by coding GWAS hits (Extended 
Data Figure 8). Notable examples include SNPs associated with Alzheimer’s disease and 
migraine, which map to enhancers and promoters active in brain tissues, and SNPs 
associated with fasting blood glucose, which map to elements active in pancreatic islets. 
Nearly all of the autoimmune diseases preferentially mapped to enhancers and promoters 
active in CD4+ T-cell subpopulations. However, a few diseases, such as systemic lupus 
erythematosus, Kawasaki disease, and primary biliary cirrhosis, preferentially mapped to B-
cell elements. Notably, ulcerative colitis also mapped to gastrointestinal tract elements, 
consistent with its bowel pathology. While the primary signature of type 1 diabetes SNPs is 
in T-cell enhancers, there is also enrichment in pancreatic islet enhancers (p<10−7). Thus, 
while immune cell effects may be shared among autoimmune diseases, genetic variants 
affecting target organs such as bowel and pancreatic islets may shape disease-specific 
pathology.
Causal Variants Map to Discretely-Regulated Elements Within Super-Enhancers
Genomic loci that encode cellular identity genes frequently contain large regions with 
clustered or contiguous enhancers bound by transcriptional co-activators and marked by 
H3K27ac. Recent studies showed that such ‘super-enhancer’ regions are enriched for 
GWAS catalog SNPs, including those related to autoimmunity18,19. Consistently, we find 
that PICS SNPs are 7.5-fold enriched in CD4+ T-cell super-enhancers, relative to random 
SNPs from the genome. We therefore parsed the topography of super-enhancers in immune 
cells using our genetic and epigenetic data.
The IL2RA locus exemplifies the complex landscape of enhancer regulation. IL2RA encodes 
a receptor with key roles in T-cell stimulation and Treg function15. The super-enhancer in 
this locus comprises a cluster of elements recognizable as distinct H3K27ac peaks (Fig 4A). 
Although the region meets the super-enhancer definition in multiple CD4+ T-cell types18, 
sub-elements are preferentially acetylated in Treg, Th17 and/or Thstim T-cells, consistent 
with differential regulation. Some sub-elements appear bound by T-cell master regulators, 
including FOXP3 in Tregs, TBET in Th1 cells, and GATA3 in Th2 cells. A systematic 
analysis indicates PICS SNPs are most enriched at distinct stimulus-dependent H3K27ac 
peaks within super-enhancer regions (Extended Data Figure 7).
PICS SNPs for eight autoimmune diseases map to distinct segments of the IL2RA super-
enhancer. For example, Immunochip data identify a candidate causal SNP for MS that has 
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no effect on autoimmune thyroiditis disease risk. Conversely, a candidate causal SNP for 
autoimmune thyroiditis has no effect on MS risk, despite the proximity of the two SNPs 
within the super-enhancer (Fig 4B). Furthermore, index SNPs for multiple other diseases are 
not in LD, suggesting that multiple sites of nucleotide variation in the locus have separable 
disease associations (Fig 4C). The distribution of PICS SNPs and the partially discordant 
regulation of sub-regions suggest that super-enhancers may comprise multiple discrete units 
with distinct regulatory signals, functions and phenotypic associations.
Disease Variants Map to TF Binding Sites, but Infrequently Disrupt Consensus Motifs
The enrichment of candidate causal variants within enhancers suggests that they affect 
disease risk by altering gene regulation, but does not distinguish the underlying mechanisms. 
Enhancer activity is dependent on complex interplay between TFs, chromatin, noncoding 
RNAs and tertiary interactions of DNA loci27. A straightforward hypothesis is that disease 
SNPs alter TF binding. Indeed, PICS SNPs tend to coincide with nucleosome-depleted 
regions, characterized by DNase hypersensitivity and localized (~150 bp) dips in H3K27ac 
signal26, which are indicative of TF occupancy (Fig 5A).
We therefore overlapped PICS SNPs with 31 TF binding maps generated by ENCODE26 
(Fig 5B). Candidate causal SNPs are strongly enriched within binding sites for immune-
related TFs, including NFκB, PU1, IRF4, and BATF. Variants associated with different 
diseases correlate to different combinations of TFs that control immune cell identity and 
response to stimulation. For example, MS SNPs preferentially coincide with NFκB, EBF1 
and MEF2A-bound regions, whereas rheumatoid arthritis and celiac disease SNPs 
preferentially coincide with IRF4 regions.
Next, we examined whether causal variants disrupt or create cognate sequence motifs 
recognized by these TFs. We focused on 823 of the highest-likelihood noncoding PICS 
SNPs, an estimated 30% of which represent true causal variants. We identified PICS SNPs 
that alter motifs for NFκB (n=2), AP-1 (n=8), or ETS/ELF1 (n=5). Overall, we identified 7 
known TF motifs and 6 conserved sequence motifs28,29 with a significant tendency to 
overlap causal variants likely to alter binding affinity. Of the highest-likelihood SNPs, 7% 
affected one of these over-represented motifs, with a roughly equal distribution between 
motif creation and disruption (Extended Data Fig 9).
A notable motif-disrupting PICS SNP is the Crohn’s disease-associated variant rs17293632 
(C>T, minor allele increases disease risk; PICS probability~54%), which resides in an intron 
of SMAD3 (Fig 5C). SMAD3 encodes a TF downstream of transforming growth factor-β 
(TGF-β) with pleiotropic roles in immune homeostasis30. The SNP disrupts a conserved 
AP-1 consensus site. ChIP-seq data for AP-1 factors (Jun, Fos) in a heterozygous cell line 
reveal robust binding to the reference sequence, but not to the variant sequence created by 
the SNP. As described above, a prominent AP-1 signature is associated with enhancers 
activated upon immune stimulation (Fig 2A). This suggests that rs17293632 may increase 
Crohn’s disease risk by directly disrupting AP-1 regulation of the TGF-β-SMAD3 pathway.
Despite this and other compelling examples, only ~7% of the highest-likelihood noncoding 
PICS SNPs alter an over-represented TF motif. Scanning a large database of TF motifs, we 
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found that ~13% of high-likelihood causal SNPs create or disrupt some known consensus 
sequence derived by in vitro selection28, while ~27% create or disrupt a putative consensus 
sequence derived from phylogenetic analysis29. However, these proportions are similar to 
the rate for background SNPs (Fig 5D). Even extrapolating for uncertainty in causal SNP 
assignments, our data suggest that at most 10–20% of noncoding GWAS hits act by altering 
a recognizable TF motif.
Notwithstanding their infrequent coincidence to the precise TF motifs, noncoding PICS 
SNPs have a strong tendency to reside in close proximity to such sequences. Candidate 
causal variants are most significantly enriched in the vicinity of NFκB, RUNX1, AP1, 
ELF1, and PU1 motifs (Extended Data Fig 9), with 26% residing within 100 bp of such a 
motif. These findings parallel recent studies of genetic variation in mice, where DNA 
variants affecting NFκB binding are dispersed in the vicinity of the actual binding sites31. 
Our results suggest that many causal noncoding SNPs modulate TF-dependent enhancer 
activity (and confer disease risk) by altering adjacent DNA bases whose mechanistic roles 
are not readily explained by existing gene regulatory models.
Functional Effects of Disease Variants on Gene Expression
To assess the effects of autoimmunity-associated genetic variation on gene regulation, we 
incorporated a recent study that mapped variants associated with heritable differences in 
peripheral blood gene expression32. We used PICS to predict causal expression quantitative 
locus (eQTL) SNPs, which we compared against random SNPs from the same loci. These 
eQTL SNPs are strongly enriched in promoters (9%) and 3′ UTRs (25%), but show 
relatively modest preference for immune enhancers (14%), compared to GWAS SNPs (Fig 
6A). Overall, ~12% of causal noncoding autoimmune disease variants also score as eQTL 
SNPs (Extended Data Figure 10). Disease SNPs that did not score as eQTLs in peripheral 
blood may score in more precise immune subsets in relevant regulatory contexts. 
Nonetheless, their modest overlap with eQTLs and their striking correspondence to 
enhancers suggest that most disease variants exert subtle and highly context-specific effects 
on gene regulation.
Incorporation of eQTL SNPs allowed us to link causal noncoding disease variants to specific 
genes. For example, PICS fine-mapping identified two SNPs in the IKZF3 locus with 
independent effects on IKZF3 expression, rs12946510 and rs907091. IKZF3 is an IKAROS 
family TF with key roles in lymphocyte differentiation and function33. Interestingly, the 
minor allele of rs12946510 is associated with decreased IKZF3 expression and increased 
MS risk (Fig 6B–C), whereas the minor allele of rs907091 is associated with increased 
IKZF3 expression, but does not affect disease risk. This suggests that disease risk is 
dependent on the specific mode and context in which a variant influences gene expression.
Despite strong evidence from fine-mapping that rs12946510 is the causal SNP affecting MS 
risk and IKZF3 expression, the underlying sequence does not reveal a clear mechanism of 
action. The disease SNP resides within a conserved element with enhancer-like chromatin in 
immune cells. It coincides with a nucleosome-depleted, DNase hypersensitive site bound by 
multiple TFs, including immune-related factors RUNX3, RELA (NFκB family member), 
EBF1, POU2F2 and MEF2 (Fig 6D). The C/T variation at this site does not create or disrupt 
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a readily recognizable consensus DNA motif, but overlaps a highly degenerate MEF2 motif 
and might thus modulate TF binding despite incomplete sequence specificity. This example 
illustrates the value of integrative functional genomic analysis for investigating the complex 
mechanisms by which noncoding variants modulate gene expression and disease risk.
Discussion
Interpretation of noncoding disease variants, which comprise the vast majority of GWAS 
hits, remains a momentous challenge due to haplotype structure and our limited 
understanding of the mechanisms and physiological contexts of noncoding elements. Here 
we addressed these issues through combination of high-density genotyping and epigenomic 
data. Focusing on autoimmune diseases, we triaged causal variants based solely on genetic 
evidence and integrated chromatin and TF binding maps to distinguish their likely functions 
and physiologic contexts. We found that most causal variants map to enhancers and 
frequently coincide with nucleosome-depleted sites bound by immune-related TFs. The 
resulting resource highlights specific TFs, target loci and pathways with disease-specific or 
general roles in autoimmunity.
Yet despite their close proximity to immune TF binding sites, only a fraction of causal 
noncoding variants alter recognizable TF sequence motifs. Moreover, disease variants have 
a distinct functional distribution and infrequently overlap peripheral blood eQTLs, which 
suggests that they exert highly contextual regulatory effects. Although these features of 
noncoding disease variants further challenge GWAS interpretation, they might not be 
unexpected. Biochemical and genetic manipulations have established the potential of motif-
adjacent sequences to influence TF activity34. Roles for such non-canonical sequences are 
also supported by the extended nucleotide conservation at many enhancers, most of which 
lies outside of known motifs, and the complex structural interactions and looping events that 
underlie gene regulation27. Furthermore, common variants contributing to polygenic 
autoimmunity are expected to have modest, context-restricted effects, given that strongly 
deleterious mutations would be eliminated from the population1. Compared to mutations 
that disrupt TF motifs, alterations to non-canonical determinants may produce subtle but 
pivotal alterations to the immune response, without reaching a level of disruption that would 
result in strong negative selection.
Systematic integration of fine-mapped genetic and epigenetic data implies a nuanced 
complexity to disease variant function that will continue to push the limits of experimental 
and computational approaches. Much work remains to be done to characterize SNPs whose 
causality can be firmly established through genotyping and to facilitate efforts to resolve 
GWAS signals that remain refractory to fine-mapping due to haplotype structure. 
Understanding their regulatory mechanisms could have broad implications for autoimmune 
disease biology and treatment, given genetic links to immune regulators, such as NFκB, 
IL2RA and IKZF3 (AIOLOS), and implied transcriptional and epigenetic aberrations, all of 
which are candidates for therapeutic intervention.
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Supplementary Methods
Cell Isolation and Culture
Purification and Culture of Human CD4+ T-cell Subsets—Cells were obtained from 
the peripheral blood of pooled healthy subjects in compliance with Institutional Review 
Board (Yale University and Partners Human Research Committee) protocols. Untouched 
CD4+ T cells were isolated by gradient centrifugation (Ficoll-Hypaque; GE Healthcare) 
using the RosetteSep Human CD4+ T cell Enrichment kit (Stemcell Technologies). CD4+ T 
cells were next subjected to anti-CD25 magnetic bead labeling (Miltenyi Biotech), to allow 
magnetic cell separation (MACS) of CD25+ and CD25− cells. Subsequently CD25+ cells 
were stained with fluorescence-labeled monoclonal antibodies to CD4, CD25 and CD127 
(BD Pharmingen), and sorted using a FACS ARIA (BD Biosciences) for 
CD25highCD127low/− Treg cells, which express FOXP3 (Biolegend) as confirmed by 
intracellular post-sort analysis by FACS (Extended Data Fig. 6). Dead cells were excluded 
by Propidium iodide (BD). An aliquot of CD25− cells was labeled with fluorescence-labeled 
monoclonal antibodies to CD4, CD45RA and CD45RO (BD Pharmingen), and sorted on a 
FACS ARIA to isolate CD45RO+CD45RA− memory (Tmem) and CD45RO−CD45RA+ 
naïve (Tnaive) CD4+ T-cell populations. Dead cells were excluded by Propidium iodide. 
Highly pure human Th17 cells were isolated with modifications as previously described35. 
In brief, CD25− cells were stimulated in serum-free X-VIVO15 medium (BioWhittaker) 
with PMA (50ng ml−1) and ionomycin (250ng ml−1; both from Sigma-Aldrich) for 8 hours 
and sorted by a combined MACS and FACS cell sorting strategy based on surface 
expression of IL-17A. Stimulated cells were stained with anti-IL-17A-PE (Miltenyi) and 
labeled with anti-PE microbeads (Miltenyi) and subsequently pre-enriched over an LS 
column (Miltenyi). The IL-17A negative fraction was used as control population (Thstim). 
MACS-enriched Th17 cells were further sorted on a FACS ARIA (BD) for highly pure 
IL-17A+ cells (Th17).
Purification of Human Naïve and Memory CD8+ T cells—Leukocyte-enriched 
fractions of peripheral blood (byproduct of Trima platelet collection) from anonymous 
healthy donors were obtained from the Kraft Family Blood Donor Center (DFCI, Boston, 
MA) in compliance with the institutional Investigational Review Board (Partners Human 
Research Committee) protocol. For two independent purifications of each cell subset, blood 
fractions from 7 and 8 donors were pooled. Total T cells were isolated by immunodensity 
negative selection using the RosetteSep Human T-cell Enrichment Cocktail (STEMCELL 
Technologies, Vancouver, Canada) and gradient centrifugation on Ficoll-Paque PLUS (GE 
Healthcare, Pittsburgh, PA), according to the manufacturer’s instructions. Subsequently, T 
cells were stained at 4°C for 30 min using fluorescently-labeled monoclonal anti-human 
CD8 (FITC, 2.5 μg/ml, clone RPA-T8, Biolegend, San Diego, CA), CD4 (PE, 1.25 μg/ml, 
clone RPA-T4, Biolegend), CD45RA (PerCP-Cy5.5, 2.4 μg/ml, clone HI100, eBioscience, 
San Diego, CA) and CD45RO (APC, 0.6 μg/ml, clone UCHL1, eBioscience) antibodies 
diluted in staining buffer (PBS supplemented with 2% fetal bovine serum, FBS). 4′,6-
diamidino-2-phenylindole (DAPI, 2.5 μg/ml, Life Technologies, Grand Island, NY) was also 
included to stain for dead cells. After washing with staining buffer, naïve 
(CD45RA+CD45RO−) and memory (CD45RA−CD45RO+) CD8+ or CD4+ were isolated 
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using a BD FACSAria 4-way cell sorter (BD Biosciences, San Jose, CA). Cell subsets were 
identified using a BD FACSDiva Software (BD Biosciences) after gating on lymphocytes 
(by plotting forward versus side scatters) and excluding aggregated (by plotting forward 
scatter pulse height versus pulse area), dead (DAPI+), and CD8/CD4 double positive cells 
(Extended Data Fig. 6). Cell purity was 90-94% CD8+ or 97–99% CD4+, and >99% naïve or 
memory.
Purification of Human B Centroblasts—Cells were obtained in compliance with 
Institutional Review Board (Partners Human Research Committee) protocols. For 
purification of human centroblasts, bulk mononuclear cells were isolated from fresh 
pediatric tonsillectomy specimens by mechanical disaggregation and Ficoll-Paque 
centrifugation36. MACS enrichment of germinal center cells was performed using anti-
CD10-PE-Cy7 (BD Biosciences), and anti-PE microbeads (Miltenyi Biotec). Centroblasts37 
(CD19+CD10+CXCR4+CD44−CD3−) were purified from the enriched germinal center cells 
by FACS antibodies for CD19 (APC, clone SJ25C1, BD), CD3 (BV606, clone OKT3, 
Biolegend), CD10 (PE-Cy7, clone HI10A, BD), CD44 (FITC, clone L178, BD) and CXCR4 
(PE, clone 12G5, eBioscience) (Extended Data Fig. 6).
Purification of Adult Human Peripheral Blood B Cells and Monocytes—Human 
peripheral B cells and monocytes were provided by the S. Heimfeld Laboratory at the Fred 
Hutchinson Cancer Research Center. The cells were obtained from human leukapheresis 
product using standard procedures. Briefly, Peripheral B cells (CD20+CD19+) and 
monocytes (CD14+) were isolated by immunomagnetic separation using the CliniMACS 
affinity-based technology (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according 
to the manufacturer’s recommendation. Reagents, tubing sets, and buffers are purchased 
from Miltenyi Biotec.
ChIP-Seq
Following isolation (+/− ex vivo stimulation), cells were cross-linked in 1% formaldehyde at 
room temperature or 37°C for 10 minutes in preparation for ChIP. Chromatin 
immunoprecipitation and sequencing were performed as previously described38. Datasets 
were publicly released upon verification at epigenomeatlas.org.
RNA-Seq
RNA was extracted from CD4+ T-cell subsets with Trizol. Briefly, polyadenylated RNA 
was isolated using Oligo dT beads (Invitrogen) and fragmented to 200–600 base pairs and 
then ligated to RNA adaptors using T4 RNA Ligase (NEB), preserving strand of origin 
information as previously described39,40.
Enhancer Annotation and Clustering
ChIP-seq data were processed as previously described38. Briefly, ChIP-seq reads of 36 bp 
were aligned to the reference genome (hg19) using the Burroughs-Wheeler Alignment tool 
(BWA)41. Reads aligned to the same position and strand were only counted once. Aligned 
reads were extended by 250 bp to approximate fragment sizes and then a 25-bp resolution 
chromatin map was derived by counting the number of fragments overlapping each position. 
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H3K27ac and H3K4me1 peaks were identified by scanning the genome for enriched 1kb 
windows and then merging all enriched windows within 1kb, using as a threshold 4 genome-
normalized reads per base pair38. Adjacent windows separated by gaps less than 500bp in 
size were joined. H3K27ac peaks that do not overlap ±2.5 kb region of an annotated TSS 
were defined as candidate distal regulatory elements. In order to define the cell-specific 
H3K27ac peaks, we calculated the mean signal in 5Kb regions centered at distal H3K27ac 
peaks and sorted the peaks by the ratio of signal in one cell type to all remaining cell types. 
For each cell type, the top 1000 distal H3K27ac peaks with highest ratio were cataloged as 
the cell-specific distal H3K27ac peaks. The heatmaps for H3K27ac and H3K4me1 signal 
were plotted over 10kb regions surrounding all distal cell-specific H3K27ac peaks.
The distal H3K27ac peaks were assigned to their potential target genes if they locate in the 
gene body or within 100kb regions upstream the TSS. Expression levels of the target genes 
were derived from RNA-seq data. Paired-end RNA-seq reads were aligned to RefSeq 
transcripts using Bowtie242. RNA-seq data for B cells, B centroblast, Macrophages, Th1, 
Th2 and Th0 were retrieved from NCBI GEO and SRA database (Bnaive: GSE45982; 
BgerminalCenter: GSE4598243; Macrophages: GSE3695244; Th0, Th1 and Th2: 
SRA08267010). RNA-seq data for lymphoblastoid (GM12878) was retrieved from 
ENCODE project26. The number of reads per kilobase per million reads (RPKM) was 
calculated for each gene locus. Heatmap of RNA-seq data shows the average relative 
expression of all potential target genes for each cluster of cell type-specific regulatory 
elements.
Shared Genetic Loci for Common Human Diseases
Publicly available GWAS catalog data were obtained from the NHGRI website, http://
www.genome.gov/gwastudies/, current as of July 201345,46. Studies were included based on 
the criteria that they had at least 6 hits at the genome-wide significant level of p ≤ 5 ×10−8. 
From a set of 21 autoimmune diseases and 18 representative non-autoimmune diseases/
traits, we included index SNPs with significance p ≤ 10−6 for downstream analysis.
In some cases, the same disease had multiple index SNPs mapping to the same locus 
(defined as within 500kb of each other), due to independently conducted GWAS studies 
identifying different lead SNPs within the same region. For these loci, only the most 
significant GWAS index SNP was kept for downstream analysis, resulting in 1170 GWAS 
index SNPs for 39 diseases/traits. For each pair of diseases/traits, we compared their 
respective lists of index SNPs to find instances of common genetic loci (defined as the two 
diseases sharing index SNPs within 500kb of each other). The number of overlapping loci 
was calculated for each disease pair. To measure the genetic similarity between two 
diseases/traits, a disease-by-disease correlation matrix was calculated based on the number 
of overlapping loci for each disease/trait with each of the other diseases, and the results are 
shown in Fig. 1A.
Sources of Immunochip and Non-Immunochip GWAS Data
Summary statistics for published Immunochip studies of celiac disease47, autoimmune 
thyroiditis48, primary biliary cirrhosis49, and rheumatoid arthritis50 were downloaded from 
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the Immunobase website, http://www.immunobase.org/. Full genotype data and PCA 
analysis for the multiple sclerosis Immunochip GWAS study20 was provided by the 
International Multiple Sclerosis Genetics Consortium. For ankylosing spondylitis51, atopic 
dermatitis52, primary sclerosing cholangitis53, juvenile idiopathic arthritis54, and psoriasis55, 
Immunochip studies had been previously been published, but only the lead SNPs from 
associated Immunochip regions were available. We also included GWAS of autoimmune 
diseases that had not been studied using Immunochip, including asthma, allergy, Kawasaki 
disease, Behcet’s disease, vitiligo, alopecia arreata, systemic lupus erythematosis, systemic 
sclerosis, type 1 diabetes, Crohn’s disease, and ulcerative colitis. For these diseases and the 
18 representative non-immune diseases, index SNPs from the GWAS catalog were used46. 
In addition, full genotype data and PCA analysis for the inflammatory bowel disease 
Immunochip GWAS study were provided by the International Inflammatory Bowel Diseases 
Genetics Consortium for purposes of calculating the statistical models used in PICS. 
Because the results for the IBD Immunochip analysis are unpublished, we used the 
previously published index SNP results for inflammatory bowel disease from the GWAS 
catalog.
Probabilistic Identification of Causal SNPs (PICS)
We developed a fine-mapping algorithm, which we call Probabilistic Identification of 
Causal SNPs (PICS), that makes use of densely-mapped genotyping data to estimate each 
SNP’s probability of being a causal variant, given the observed pattern of association at the 
locus. We developed PICS on large multiple sclerosis (MS) (14277 cases, 23605 controls20) 
and inflammatory bowel disease (IBD) cohorts (34594 cases, 28999 controls; unpublished 
data) that were genotyped using the Immunochip, a targeted ultra-dense genotyping array 
with comprehensive coverage of 1000 Genomes Project SNPs22 within 189 autoimmune 
disease-associated loci.
Analysis of IBD risk associated with SNPS at the IL23R locus presents an illustrative 
example of the LD problem and the potential for PICS to overcome this challenge (Extended 
Data Fig. 1). The most strongly associated SNP is rs11209026, a loss of function missense 
variant that changes a conserved arginine to glutamine at amino acid position 381 (R381Q) 
and decreases downstream signaling through the STAT3 pathway56,57. Association with 
IBD decreases with physical distance along the chromosome, due to rare recombination 
events that break up the haplotype and distinguish the causal missense mutation from other 
tightly linked neutral variants. These rare informative recombination events would be 
missed by standard genotyping arrays with probes spread thinly across the entire genome.
For neutral SNPs whose association signal is only due to being in LD with a causal SNP, the 
strength of association, as measured by chi-square (or log-pvalue, since chi-square and log-
pvalue are asymptotically linear) scales linearly with their r2 to the causal SNP. This is 
because strength of association is linear with r2 by the formula for the Armitage Trend 
Test58:
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where χ2 is the chi-square association test statistic, n is the sample size, and r2 is the square 
of the correlation coefficient.
This linear trend is observed at the IL23R locus, consistent with a model where R381Q is the 
causal variant, and neutral SNPs demonstrate association signal in proportion to their LD to 
the causal variant (Extended Data Fig. 1). SNPs in linkage to R381Q do not perfectly fall on 
the expected line, due to statistical fluctuations. Independent association studies for the same 
disease tend to nominate different SNPs within a given locus as their best association, due to 
statistical fluctuation pushing a different SNP to the forefront in each subsequent study59–62. 
Note that a group of SNPs that are strongly associated to disease but are not in linkage with 
rs11209026 (R381Q) represent independent association signals at the locus.
Although we know from functional studies that R381Q is the likely causal variant, we 
sought additional statistical evidence to support R381Q as the causal variant, and to refute 
the null hypothesis that the prominent association of R381Q (compared to other SNPs in the 
haplotype) is due to chance. We simulated 1000 permutations by fixing the association 
signal at R381Q, but with all other SNPs being neutral, while preserving the LD 
relationships between SNPs in the locus. An odds ratio of 1.2 was used rather than the ~2-
fold odds ratio naturally observed at R381Q, because this was more representative of the 
modest association signal strengths observed at other GWAS loci. For each round of 
permutation, we obtained the association signal at all SNPs in the locus. Because only the 
association signal at R381Q is fixed, the signal at the remaining neutral SNPs in the locus 
are free to vary due to statistical fluctuations; four typical examples of simulated association 
results at the R381Q locus are shown (Extended Data Fig. 1), including two examples where 
the causal variant is not the most strongly associated SNP in the locus. From these 1000 
iterations, we calculated the standard deviation in the association signal for each of the SNPs 
in the IL23R locus (Extended Data Fig. 2). We show that the distribution of association 
signals for each SNP approximates a normal distribution, centered at the expected value 
based on that SNP’s r2 to the causal variant (Extended Data Fig. 2).
These permutations demonstrate that the causal variant need not be the most strongly 
associated SNP within the locus, due to statistical fluctuations. Rather, given the observed 
pattern of association at a locus, we are interested in knowing the probability of each SNP 
within the locus to be the causal variant. We can use Bayes’ theorem to infer the probability 
of each SNP being the causal variant, by using information derived from the permutations. 
Since the prior probability of each SNP to be the causal variant is equal, the SNP most likely 
to be the causal variant is therefore the SNP whose simulated signal most closely 
approximates the observed association at the locus. By performing permutations of a 
simulated association signal at each SNP within the locus, we can estimate the probability 
that the SNP could lead to the observed association at the locus.
For example, consider a two SNP example where SNP A and SNP B are in LD, and SNP A 
is the lead SNP in the locus (Extended Data Fig. 2). If we are interested in knowing 
P(Bcausal|Alead), i.e. the probability that SNP B is the causal variant given that SNP A is the 
top signal in the locus, then by Bayes’ theorem:
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Where P(Alead|Bcausal) is the probability of SNP A being the top signal in the locus, given 
that SNP B is the causal variant. P(Alead|Bcausal) is straightforward to calculate by 
performing permutations with a simulated signal at SNP B, and measuring the number of 
permutations where SNP A emerges as the top signal in the locus despite SNP B being the 
actual causal variant. We have assumed that the prior probability of each SNP to be the 
causal variant or the lead SNP is equal, although this could be adjusted based on external 
information, such as functional annotation of the SNP to be a coding variant.
Using the formula above, we calculate both P(Bcausal|Alead) and P(Acausal|Alead), and then 
normalize both of these probabilities so that P(Bcausal|Alead) + P(Acausal|Alead) = 1. In cases 
where there are more than two SNPs to consider, we similarly normalize the probabilities so 
that they sum to 1. Probabilities were calculated for all SNPs with r2 > 0.5 to the lead SNP.
Because the calculation of thousands of permutations is computationally expensive and 
requires full genotype data, we sought to generalize the results of the permutation-based 
method in order to extend it to the analysis of autoimmune diseases for which Immunochip 
data were not available, or only the identity of the lead index SNPs was reported, such as 
from the GWAS catalog. We developed a general model, where PICS was able to calculate 
P(Bcausal|Alead), where B is a SNP within a locus, and A is the lead SNP in the locus, by 
using LD relationships from the Immunochip where these were available, and from the 1000 
Genomes Project otherwise. Since the distribution of association signal at neutral SNPs in 
the locus approximates a normal distribution, given the lead SNP in the locus, we need to be 
able to estimate the mean expected association for a neutral SNP in LD with the lead SNP, 
and the standard deviation for that SNP.
The expected mean association signal for SNPs in the locus scales linearly with r2 to the 
causal SNP in the locus. We derived an approximation for the standard deviation for each 
SNP in the locus based on the results of empiric testing. We picked 30,000 random SNPs 
from densely-mapped Immunochip loci, with half coming from the MS Immunochip data, 
and half coming from the IBD Immunochip data. For each SNP, we simulated 100 
permutations with that SNP being the causal variant. SNPs selected had minor allele 
frequency above 0.05, and the odds ratio used varied from 1.1 fold to 2.0 fold. The number 
of cases and controls and total sample size were also allowed to randomly vary from 1%–
100% of the total number of samples in the original studies. These results indicated that the 
standard deviation for the association signal at a SNP in LD (with r2>0.5) to a causal variant 
in the locus was approximately:
where s is the standard deviation of the association signal at the SNP, m is the expected 
mean of the association signal at the SNP, indexpval is the −log10(p-value) of the causal 
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SNP in the locus, r2 is the square of the correlation coefficient (a measure of LD) between 
the SNP and the causal SNP in the locus, and k is an empiric constant that can be adjusted to 
fit the curve; in practice, we found that choosing k from a wide range of values between 6 
and 8 had little measurable effect on the candidate causal SNPs selected, and we used a 
value of k=6.4. The results of the 30,000 simulated iterations and the empiric curve fitted 
using the above equation is shown in Extended Data Fig. 3. To verify that our method was 
applicable to a wide range of case-control ratios and effect sizes, we performed six 
additional simulations, with the percentage of case samples fixed at 10%, 20%, and 50%, 
and the effect sizes of causal SNPs fixed at 1.2-fold, 1.5-fold, and 2.0-fold, which cover a 
broad range of parameters likely to be encountered in practical GWAS studies (Extended 
Data Fig. 3). We found that for all six scenarios, the relationship between r2 to the causal 
SNP and standard deviation similarly followed the empirically fitted curve.
For each SNP in the locus, we used the estimated mean and standard deviation of the 
association signal at each neutral SNP in LD (r2 > 0.5) to the lead SNP in the locus to 
calculate the probability of each SNP to be the causal variant relative to the lead SNP. We 
then normalized the probabilities so that the total of their probabilities summed to 1.
For diseases where summary SNP information was available, but the r2 relationships 
between SNPs was unknown, the r2 relationship was estimated based on the ratio between 
the association signal at the lead SNP versus the SNP in question. For diseases where only 
the lead SNP was known, r2 values were drawn from the LD relationships from the MS 
Immunochip study if the SNP was from an Immunochip, or from the 1000 Genomes Project 
otherwise. 1000 Genomes European LD relationships were used for diseases, except for 
Kawasaki disease, for which 1000 Genomes East Asian LD relationships were used. For 
diseases which had both GWAS catalog results and Immunochip results, we used 
Immunochip results whenever possible, and GWAS catalog results in regions outside 
Immunochip dense-mapping coverage.
Multiple Independent Association Signals
For the MS data, we were able to use full genotyping information to distinguish multiple 
independent signals. We used stepwise regression to condition away SNPs one at a time 
until no associations remain at the p<10−6 level, which is an effective method for separating 
independent signals, when LD between the independent causal variants is low. We then 
treated each independent signal separately for the purpose of using PICS to derive the likely 
causal variants.
Missing Immunochip Data
For the minority of SNPs that were missing from the Immunochip, we used 1000 Genomes 
SNPs LD relations to the index SNP to estimate their probability of being the causal SNP. 
For the diseases with only Immunochip summary statistic data, we could not be certain of 
the LD relationships, and therefore we estimated the LD to the index SNP from the 
difference between the association at the lead SNP and the SNP in question, since these 
follow a linear relationship. For the diseases that only had Immunochip index SNP data, we 
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used Immunochip LD relationships where available from the MS data, and 1000 Genomes 
SNPs LD relations to the index SNP where these were not available.
Distance between GWAS Catalog SNPs and Lead SNPs
For Immunochip regions that were previously studied by non-Immunochip studies, we 
examined the performance of prior non-fine-mapped studies at correctly determining the 
lead SNP. GWAS catalog SNPs within 200kb of Immunochip regions were considered, and 
the LD and genomic distance between the catalog SNP and any Immunochip lead SNPs for 
that disease in the Immunochip region were measured and reported in the histograms in Fig. 
1D and Extended Data Fig. 5. PICS was also used to calculate the probability of GWAS 
catalog SNPs to be causal variants; the probability was 5.5% on average.
Number of Candidate Causal SNPs per GWAS Signal
For each GWAS signal, we obtained a set of candidate causal SNPs, each with a probability 
of being the causal variant. For each signal, we asked what was the minimum number of 
candidate causal SNPs required to to cover at least 75% of the probability (Fig. 1E).
Distribution of GWAS Signals in Functional Genomic Elements: Signal to Background
For downstream analyses, we considered the set of 4905 candidate causal SNPs which had 
mean probability of greater than 10% of being the candidate causal SNP (the cutoff was 
probability > 0.0275). We performed 1000 iterations, picking 4905 minor-allele-frequency-
matched random SNPs from the same loci (from genomic regions within 50kb of the 
candidate causal SNPs and excluding the actual causal SNPs). It was necessary to match for 
minor-allele-frequency because lower MAF SNPs are far more likely to be coding variants. 
Furthermore, it was necessary to match for locus, because GWAS SNPs are greatly enriched 
at gene bodies, and using a background of random 1000 genome SNPs for comparison 
results in massive nonspecific enrichment of all functional elements. Because we are 
comparing the candidate causal SNPs to a background set of control SNPs from the same 
regions, the observed enrichments at functional elements strongly argues that PICS 
effectively predicts causal variants within the loci. For each functional category (missense, 
nonsense, and frameshift were merged), we calculated the number of actual candidate causal 
SNPs above mean background (mean of 1000 random iterations), divided by the total 
number of GWAS signals represented (635), and used these results to populate the pie chart 
indicating the approximate percentage of GWAS signals that can be attributed to each 
assessed functional category (Fig. 6).
Analysis of ex vivo Stimulation-dependent Enhancers
We searched for motifs enriched in cell type-specific enhancers in the five stimulated T-cell 
subsets (PMA/Ionomycin stimulated Thstim and Th17 T-cells, anti-CD3/CD28 stimulated 
Th0, Th1, and Th2 T-cells) compared to enhancers in naïve T-cells, using the motif finding 
program HOMER (http://homer.salk.edu/homer/)63. AP-1 was the most strongly enriched 
motif in enhancers that gained H3K27ac in the stimulated T-cells (Fig. 2), whereas this 
enrichment was absent when comparing naïve T-cells with memory or regulatory T-cells. 
Additional motifs that were enriched in the stimulation-dependent enhancers included 
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NFAT for the PMA/Ionomycin stimulation conditions and STAT for the anti-CD3/CD28 
stimulation condition.
Enhancer Signal-to-noise Analysis
We focused on 14 immune cell types (8 CD4+ T-cell subsets, 2 CD8+ T-cell subsets, CD14+ 
monocytes, and 3 B-cell subsets) and 19 representative non-immune cell/tissue types from 
the Roadmap Epigenomics project. Enhancers were broken up into 1kb segments and 
immune specific enhancers were identified based on the following criteria: (1) # of 
normalized mean H3K27ac ChIP-seq extended reads/base > 4, and (2) mean H3K27ac in the 
top 15th percentile when comparing immune cells to non-immune cells/tissues. We 
measured the percentage of PICS SNPs (with different probability cutoffs) that either map to 
an immune enhancer or cause an amino acid coding change (Fig. 2). We next considered the 
4300 candidate causal SNPs that were not associated with protein coding changes, and 
compared them against 1000 iterations of frequency and locus matched controls (picked 
from genomic regions within 50kb of the candidate causal SNPs and excluding the actual 
candidate causal SNPs; see discussion of background calculations above). Enhancers were 
enriched approximately 2:1 above background. We also measured the signal to backround 
ratio for GWAS signals that had been attributed to coding variants; these produced a much 
lower signal to background ratio for immune enhancers, as would be anticipated by the fact 
that most of these are acting on coding regions rather than enhancers (Extended Data Fig. 7). 
The mean signal above background was shown in a pie chart (Fig. 6).
Comparison to Other Methods for Determining Candidate Causal Variants
We compared the efficacy of PICS versus previously published methods used to determine 
candidate causal variants (Fig. 2D–E). We first considered studies that had used cutoffs of 
r2=1.0 and r2>0.8 to determine likely causal SNPs. Because prior studies had not made use 
of dense genotyping data, we used only the GWAS catalog results for this comparison, and 
applied PICS, and the two r2-cutoff criteria. In practice these were much more stringent than 
prior analyses, because we limited the GWAS catalog studies to those that produced 6 or 
more genome-wide significant hits, thereby pruning underpowered studies. We also required 
a significance of p<10−6 for index SNPs, and merged index SNPs at the same locus to use 
the strongest and most accurate lead SNP. We found that PICS autoimmunity SNPs were 
much more likely to map to immune enhancers than SNPs identified by the other statistics. 
In addition, when the PICS SNPs which overlapped the r2>0.8 and r2>1.0 sets were 
removed, the remaining SNPs did not show any enrichment above background. In contrast, 
the candidate causal SNPs identified by PICS, but missed by both of the other 
methodologies, were significantly enriched for immune enhancers. Background was 
calculated based on random SNPs drawn from the same loci (within 50kb, frequency-
matched controls) as the candidate causal SNPs.
We also compared PICS with a recently reported Bayesian approach64, using a recently 
published study of MS20 that employed this methodology to call candidate causal SNPs. 
Because this published method required full genotypes to be available, this comparison was 
limited to only the MS dataset. Both PICS and the published method are Bayesian 
approaches, where each SNP within the locus is given equal prior consideration to be the 
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causal variant, and the algorithm then weighs each SNP based on the likelihood of each 
model given the data. However, the PICS method provides two advantages. First, the 
probabilities assigned to each SNP by PICS are determined empirically using permutation, 
rather than using a theoretical estimate for the weight of each SNP. Second, PICS can be 
generalized to all GWAS data with publicly available summary statistic data and does not 
rely on genotype data.
For the same MS immunochip dataset, PICS called 434 candidate causal SNPs, while the 
prior method called 4070 candidate causal SNPs; 177 SNPs were shared between the two 
analyses. Of the 434 PICS candidate causal SNPs, 26.5% overlapped immune enhancers, 
whereas 9.5% of the SNPs from the other method overlapped immune enhancers; the 
background rate of random SNPs from the same loci overlapping immune enhancers was 
8% (Extended Data Fig. 4). Because the Wellcome Trust (Maller et al.) method is clearly 
less stringent than PICS, we also tried using a high confidence set of SNPs derived by that 
method, by selecting the top SNPs such that their average probability of being a causal 
variant was 10% (the same cutoff used for the PICS SNPs). There were 165 SNPs in this 
high confidence set, compared to 434 for PICS, with an overlap of 65 SNPs. 20.3% of the 
candidate causal SNPs in the high confidence Maller et al. set overlapped immune 
enhancers. Although anecdotal, these results suggest that PICS performs at least as well as 
the prior method.
Tissue-specificity of Diseases
We used PICS fine-mapping to determine the set of candidate causal SNPs for each of 39 
different diseases, and examined whether they were enriched within the enhancers most 
specific to each cell type (defined as being in the top 15th percentile of H3K27ac signal 
compared to other cell types, and with > 1 normalized mean H3K27ac ChIP-seq extended 
reads/base). To compare enhancer regions across different cell types, we first subdivided 
regions of the genome that were marked as enhancers into enhancer segments ~1kb in size. 
Next, H3K27ac read density at each enhancer segment in the genome was compared across 
all 33 cell types to determine the cell types in the top 15th percentile (H3K27ac signal was 
quantile normalized across the cell types prior to comparison). The heatmap (Fig. 3) depicts 
p-values for the enrichment of PICS SNPs for each disease in H3K27ac elements for each 
cell type, as calculated by the chi square test. For this comparative analysis, enrichment of 
PICS SNPs was measured against a background of all common 1000 Genomes SNPs. We 
used this approach because the goal was to highlight cell type-specificity of the diseases, 
which would have been normalized out by the rigorous locus controls used above, and given 
that the specificity of PICS SNPs for enhancers within the loci was already established. We 
also mapped the expression patterns of genes with PICS candidate causal coding SNPs 
associated with Crohn’s disease, MS and rheumatoid arthritis (Extended Data Fig. 8).
Super-enhancer Enrichment
The full set of loci called as super-enhancers18 in CD4+ T-cell subsets (Tnaive, Tmem, Th17, 
ThStim) were merged and identified as CD4+ T-cell super-enhancer regions. These regions 
often contain clusters of discrete enhancers marked with H3K27ac, separated by non-
acetylated regions. We assessed if PICS SNPs mapping to super-enhancers were more likely 
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to occur in H3K27ac-marked enhancer regions than in intervening regions. Within CD4+ T-
cell super-enhancer regions, we compared overlap of PICS candidate causal SNPs with 
CD4+ T-cell H3K27ac regions, compared to frequency-matched background SNPs drawn 
from these same regions (Extended Data Fig. 7). H3K27ac intervals in CD4+ T-cell super-
enhancers were called based on being in the top 15th percentile in mean H3K27ac in T-cells 
compared to the other 25 cell types. In addition, we assessed overlap between PICS SNPs 
and H3K27ac elements preferential to either stimulated or unstimulated CD4+ T-cells. 
Stimulated CD4+ T-cell elements were defined as those with a mean increase of >25% in 
H3K27ac in the (average of) Th17, ThStim, Th0, Th1, Th2 cells, compared to the Tnaive, 
Tmem, Treg; the remainder of the CD4+ T-cell set were defined as unstimulated elements.
Fig. 4 shows that some sub-elements within IL2RA super-enhancer locus appear bound by 
T-cell master regulators based on published ChIP-Seq data, including FOXP3 in Tregs, 
TBET in Th1 cells, and GATA3 in Th2 cells65,66.
Noncoding RNA Analysis
We next examined the set of disease-associated enhancers, i.e. immune enhancers 
containing PICS autoimmunity SNPs, and their association with noncoding RNAs. 
Noncoding RNA transcripts were called based on a RNA-seq read density of 0.5 genome-
normalized reads per bp over a window size of at least 2kb, excluding RNA transcripts 
overlapping annotated exons or gene bodies. We found that enhancers containing PICS 
autoimmunity SNPs were enriched for noncoding transcript production, primarily consistent 
with unspliced enhancer-associated RNAs. Candidate causal SNPs were enriched 1.6-fold 
within T-cell enhancers that transcribed noncoding RNAs, compared to T-cell enhancers 
overall (p<0.01).
H3K27ac and DNase Profiles
We measured H3K27ac profiles and DNase hypersensitivity profiles in a 12kb window 
centered around candidate causal SNPs, taking the average signal for the 14 immune cell 
types for which H3K27ac was available, and immune cell types from ENCODE26 for which 
DNase was available (CD14+, GM12878, CD20+, Th17, Th1, Th2). Average normalized 
reads for H3K27ac and DNase centered at PICS SNPs are displayed in Fig. 5A.
Transcription Factor ChIP-Seq Binding Site Analysis
We compared the enrichment of PICS autoimmunity SNPs at TF binding sites identified by 
ENCODE ChIP-Seq67, relative to random SNPs drawn from the same loci (50kb window 
around the candidate causal SNPs, frequency matched). We show the results for the 31 TFs 
whose binding sites are most significantly enriched for PICS SNPs (Fig. 5B).
Motif Creation / Disruption Analysis
We downloaded consensus motifs from Selex28 and Xie et al.29 (represented as degenerate 
nucleotide codes). We used the 853 highest probability non-coding PICS SNPs (mean 
probability = 0.30, cutoff >0.1187), representing 403 different GWAS signals. For each 
candidate causal SNP, we examined whether it created or disrupted a known motif from 
Selex or Xie et al. For comparison, we ran 1000 iterations using frequency-matched random 
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SNPs drawn from the same loci (within 50kb of the PICS SNPs). We found several known 
motifs (Extended Data Fig. 9) to be significantly enriched, including AP1, ETS, NFKB, 
SOX, PITX, as well as several unknown conserved motifs (Extended Data Fig. 9). 
Subtracting the number of motifs found to be disrupted against that expected by background, 
and dividing by the total number of GWAS signals, we estimate that approximately 11% of 
noncoding GWAS hits can be attributed to direct disruption or creation of TF binding 
motifs.
Neighboring Motif Analysis
We compared the sequence within 100nt of high-likelihood PICS SNPs (cutoff >0.1187) 
against random flanking sequence (10kb away on either side from the causal SNPs) and 
looked for enriched motifs using HOMER (http://homer.salk.edu/homer/)63. We found 
significant enrichments for NFKB, RUNX, AP1, ELF1, and PU1 (Extended Data Fig. 9). 
Interestingly, there was a palindromic unknown motif TGGCWNNNWGCCA (p<10−4) that 
was significant both in this method and in the motif disruption/creation analysis, suggesting 
a yet uncharacterized TF motif with relevance in autoimmunity.
Expression Quantitative Trait Loci (eQTL) Analysis
We used PICS to predict causal SNPs from a peripheral blood eQTL dataset with 1000 
Genomes summary statistic data available for all cis-eQTLs. We required a gene to have a 
cis-eQTL with a p-value < 10−6 for this analysis, giving us 4136 genes. For each gene we 
applied PICS. We considered a GWAS hit to score as an eQTL if any GWAS PICS SNP in 
the locus coincided with an eQTL PICS SNP with average probability >0.01%. We found 
that 11.6% (74/636) of GWAS hits were also eQTL hits. In addition, 18.5% (15/81) of 
coding GWAS hits also showed eQTL effects, suggesting that they may actually operate at 
the transcriptional level, in addition to any coding effects they may have.
To quantify overlap of candidate causal eQTL SNPs with functional elements, we compared 
PICS eQTL SNPs against frequency-matched background SNPs drawn from the same loci 
(within 50kb) in 1000 iterations. These comparisons are shown in signal-to-background bar 
graphs for both coding/transcript-related functional elements and for enhancers and 
promoters (Extended Data Fig. 10). The signal above mean background was calculated for 
each functional category, and these results were compared against the results for GWAS hits 
in the pie charts shown in Fig. 6A.
We further examined whether the magnitudes of disease-associated eQTLs differed, 
compared to the space of all eQTLs (Extended Data Fig. 10). Disease-associated variants 
had modestly larger effects on gene expression (p<10−6 by rank-sum test), but did not 
necessarily correspond to the strongest eQTLs.
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Extended Data
Extended Data Figure 1. GWAS Result for IBD Immunochip data at IL23R locus (actual data a–
c, simulated permutationd d–e)
(a) Each of the 500 SNPs in the IL23R densely genotyped locus is plotted according to its 
association signal and position along the chromosome. The R381Q missense variant is 
circled in red. (b) Each of the 500 SNPs in the IL23R densely genotyped locus is plotted 
according to its association signal and r2 linkage to R381Q. (c) Same as (b), but showing the 
association signal on the y-axis in chi-square units. Over the range of values typically 
encountered in GWAS analyses, chi-square units and log p-value are asymptotically linear. 
(d) Simulated permutation analysis of signal at IL23R locus. 1.2-fold odds ratio signal was 
simulated at the R381Q SNP by fixing the association signal at R381Q, but permuting cases 
and controls such that all other SNPs are neutral and vary only with statistical noise. Four 
representative results from the simulations are shown, with the panels on the left showing 
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the association signal in genomic space, and the panels on the right (e) showing the 
association signal for each SNP in relation to r2.
Extended Data Figure 2. Calculating the Relative Likelihood of Being the Causal SNP from 
Standard Deviation in Association Signal
(a) For each SNP in the IL23R locus, the mean association signal and the standard deviation, 
calculated across 1000 permutations (using a 1.2-fold odds ratio at the R381Q SNP), are 
shown in genomic space and (b) in terms of each SNP’s r2 linkage disequilibrium to the 
causal R381Q variant. (c) The distribution of association signals at rs77319898 (r2 = 0.71 to 
the causal variant) for 1000 permutations is shown. The distribution of association signal 
values at each SNP approximated a normal distribution. (d) PICS analysis of a two SNP 
case to determine the relative likelihood of each to explain the pattern of association at the 
locus. The SNPs represented here are R381Q (SNP A) and rs77319898 (SNP B), which has 
an r2 = 0.71 to R381Q. The signal at SNP B is well-explained by LD to SNP A, in a model 
where SNP A is treated as the putative causal variant. The error bars indicate the standard 
deviation in the association signal expected for SNP B, under the assumption that SNP A is 
causal. (e) The signal at SNP A is poorly explained by LD to SNP B, in a model where SNP 
B is treated as the putative causal variant. The error bars indicate the standard deviation in 
the association signal expected for SNP A, under the assumption that SNP B is causal.
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Extended Data Figure 3. Simulated Permutations and Empiric Curve Fitting for 30,000 GWAS 
Signals at Immunochip Loci
(a) We simulated 30,000 causal SNPs in densely mapped Immunochip regions. Plot shows 
the relationship between standard deviation in the association signal of neutral SNPs and 
their r2 to the causal SNP (neutral SNPs within r2 > 0.5 of the simulated causal variant are 
shown). The red line indicates the expected values derived from the empiric equation for the 
standard deviation of the association signal at neutral SNPs in LD with the causal SNP. (b) 
Plot shows the relationship between standard deviation in the association signals of neutral 
SNPs and the association signal of the causal SNP. Each panel represents the set of neutral 
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SNPs with the indicated r2 to the causal variant. (c) Simulated permutations over a range of 
case-control ratios. We plotted the relationship between standard deviation at neutral SNPs 
and their r2 to the causal SNP. Plots are shown for three series of simulations, with the 
percentage of cases fixed at 10%, 20%, and 50% of the total sample size, and a causal SNP 
p-value of 10−20. Red line indicates the expected values derived from the empiric equation 
for the standard deviation of the association signal at neutral SNPs in LD with the causal 
SNP in the locus. (d) Simulated permutations over a range of effect sizes. Plots are shown 
for three series of simulations, with the effect size fixed at 1.2-fold, 1.5-fold, and 2.0-fold, 
and the corresponding lead SNP p-values fixed at 10−20, 10−70, and 10−150 respectively.
Extended Data Figure 4. Comparison of PICS with prior Bayesian fine-mapping method
Bar graph shows the percentage of MS SNPs overlapping immune enhancers using different 
algorithms for calling candidate causal SNPs. The dotted line indicates the background rate 
at which random 1000 Genomes Project SNPs drawn from the same loci intersect immune 
enhancers (~8%). The categories shown are (from top to bottom): 257 SNPs called only by 
PICS, 3812 SNPs called only by the Bayesian method, 177 SNPs called by both PICS and 
the Bayesian method, all 434 SNPs called by PICS, 165 called by the Bayesian using a 
cutoff that only includes the highest confidence SNPs, and all 4070 SNPs called by Bayesian 
method.
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Extended Data Figure 5. LD Distance Between PICS lead SNPs and GWAS catalog index SNPs
Histogram indicates LD distance (in r2) between PICS fine-mapped Immunochip lead SNPs 
and previously reported GWAS catalog index SNPs from the same loci.
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Extended Data Figure 6. Purification of Human Immune Cell Subsets
(a) Immune populations subjected to epigenomic profiling in this study (red labels) or prior 
publications. (b) CD4+ cells were enriched based on CD25 expression (MACS) and 
subsequently sorted based on CD25highCD127low/− to isolate Treg cells; confirmed with 
FOXP3 intracellular staining. (c) CD4+CD25− cells were sorted to isolate Tmem 
(CD45RO+CD45RA−) and Tnaive (CD45RO−CD45RA+) cells. (d) CD4+CD25− cells were 
PMA/ionomycin stimulated and separated based on IL17 surface expression (MACS and 
FACS) to isolate Th17 cells (IL17+) and ThStim cells (IL17−). (e) Naïve 
(CD45RA+CD45RO−) and memory (CD45RA−CD45RO+) CD8+ T cells were isolated 
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using a BD FACSAria 4-way cell sorter. Results are shown from one of two large-scale 
sorts. (f) Mononuclear cells were isolated from pediatric tonsils. Following CD10 
enrichment (MACS), B centroblasts (CD19+CD10+CXCR4+CD44−CD3−) were purified by 
FACS.
Extended Data Figure 7. PICS SNPs Localize to Immune Enhancers and Stimulus-Dependent 
H3K27ac Peaks in Super-enhancers
(a) Correlation matrix of 56 cell types, clustered by similarity of H3K27ac profiles 
(high=red, low=blue). (b) Enrichment of noncoding autoimmune disease candidate causal 
SNPs within immune enhancers and promoters compared to background. The background 
expectation is based on frequency-matched control SNPs drawn from within 50kb of the 
candidate causal SNPs. Candidate causal SNPs that produced coding changes or were in LD 
with a coding variant (paired bars on the right) showed a smaller degree of enrichment in 
immune enhancers and promoters compared to background. (c) Overlap of PICS SNPs with 
H3K27ac peaks within T-cell super-enhancers. Bar plot shows overlap of PICS SNPs with 
H3K27ac peaks in super-enhancers in CD4+ T-cells, compared to random SNPs drawn from 
within the same super-enhancers (All CD4+; left bar graph). Adjacent bars show overlap to 
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H3K27ac peaks within CD4+ T-cell super-enhancers that do (Stim) or do not (Unstim) 
increase their acetylation upon stimulation.
Extended Data Figure 8. Expression Pattern of Genes with PICS Autoimmunity Coding SNPs
Heatmap shows the relative expression levels of genes with coding SNPs associated with 
Crohn’s disease, multiple sclerosis, and rheumatoid arthritis.
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Extended Data Figure. 9. Motifs Directly Altered by or Adjacent to Candidate Causal SNPs
(a) Known motifs (identified by conservation or SELEX) created or disrupted by candidate 
causal SNPs at a higher frequency than expected by chance when compared to control SNPs 
drawn from the same loci. (b) Additional motifs, identified by conservation, created or 
disrupted by candidate causal SNPs more frequently than by chance. (c) Known motifs 
significantly enriched within 100bp of candidate causal SNPs, compared to background 
control SNPs drawn from the same loci.
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Extended Data Figure 10. Enrichment of Candidate Causal eQTL SNPs in Functional Elements
(a) PICS was used to identify candidate causal SNPs for 4136 eQTL signals in peripheral 
blood. Bar plot show their overlap with indicated functional genic annotations. Background 
expectation was calculated based on frequency-matched control SNPs drawn from within 
50kb of the candidate causal SNPs. (b) Overlap of candidate causal eQTL SNPs with 
immune enhancers and promoters, versus background. (c) Magnitudes of disease-associated 
eQTLs compared to the space of all eQTLs. Histogram compares the magnitudes of PICS 
eQTL SNPs that overlap PICS autoimmunity SNPs against the full set of PICS eQTL SNPs.
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Figure 1. Genetic fine-mapping of human disease
a, GWAS catalog loci were clustered to reveal shared genetic features of common human 
diseases and phenotypes. Color scale indicates correlation between phenotypes (high=red, 
low=blue). b, Association signal to MS for SNPs at the IFI30 locus. c, Scatter plot of SNPs 
at the IFI30 locus demonstrates the linear relationship between LD distance (r2) to 
rs1154159 (red) and association signal. d, Candidate causal SNPs were predicted for 21 
autoimmune diseases using PICS. Histogram indicates genomic distance (bp) between PICS 
Immunochip lead SNPs and GWAS catalog index SNPs. e, Histogram indicates number of 
candidate causal SNPs per GWAS signal needed to account for 75% of the total PICS 
probability for that locus. f, Plot shows correspondence of PICS SNPs to indicated 
functional elements, compared to random SNPs from the same loci (error bars indicate 
standard deviation from 1000 iterations using locus-matched control SNPs).
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Figure 2. Epigenetic fine-mapping of enhancers
a, Heatmaps show H3K27ac and H3K4me1 signals for 1000 candidate enhancers (rows) in 
12 immune cell types (columns). Enhancers are clustered by the cell type-specificity of their 
H3K27ac signals. Adjacent heatmap shows average RNA-seq expression for the genes 
nearest to the enhancers in each cluster. Gray-scale (right) depicts the enrichment of PICS 
autoimmunity SNPs in each enhancer cluster (hypergeometric p-values calculated based on 
the number of PICS SNPs overlapping enhancers from each cluster, relative to random 
SNPs from the same loci). The AP-1 motif is over-represented in enhancers preferentially 
marked in stimulated T-cells, compared to naïve T-cells. b, Candidate causal SNPs 
displayed along with H3K27ac and RNA-seq signals at the PTGER4 locus. A subset of 
enhancers with disease variants (shaded) shows evidence of stimulus-dependent eRNA 
transcription. c, Stacked bar graph indicates percentage overlap with immune enhancers and 
coding sequence for PICS SNPs at different probability thresholds, compared to control 
SNPs drawn from the entire genome (All SNPs) or the same loci (Locus CTRL). d, Venn 
diagram compares PICS SNPs to GWAS catalog SNPs with indicated r2 thresholds. e, Bar 
graph indicates percentage overlap with annotated T-cell enhancers for PICS SNPs, GWAS 
SNPs at indicted thresholds, locus control SNPs, and three subsets of SNPs defined and 
shaded as in panel d.
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Figure 3. Cell-type specificity of human diseases
Heatmap depicts enrichment (red=high; blue=low) of PICS SNPs for 39 diseases/traits in 
acetylated cis-regulatory elements of 33 different cell types.
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Figure 4. Disease variants map to discrete elements in super-enhancers
a, Candidate causal SNPs for autoimmune diseases are displayed along with H3K27ac, 
RNA-seq and TF binding profiles for the IL2RA locus, which contains a super-enhancer 
(pink shade). b, For all SNPs in the IL2RA locus, scatter plot compares strength of 
association with MS versus autoimmune thyroiditis. Immunochip data resolve rs706779 
(red) as the lead SNP for autoimmune thyroiditis and rs2104286 (blue) as the lead SNP for 
MS. c, LD matrix displaying r2 between lead SNPs for different diseases at the IL2RA locus 
confirms distinct and independent genetic associations within the super-enhancer.
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Figure 5. Causal variants map to regions of TF binding
a, Plot depicts composite H3K27ac and DNase signals26 in immune cells over PICS 
autoimmunity SNPs. PICS SNPs overall coincide with nucleosome-depleted, hypersensitive 
sites, indicative of TF binding. b, Bar plot indicates TFs whose binding is enriched near 
PICS SNPs for all 21 autoimmune diseases26. Heatmap depicts enrichment of these TFs near 
variants associated with specific diseases (red:high; blue:low). c, H3K27ac, DNaseI26 and 
conservation signals, and selected TF binding intervals are shown in a SMAD3 intronic 
locus. rs17293632, a noncoding candidate causal SNP for Crohn’s disease, disrupts a 
conserved AP-1 binding motif in an enhancer marked by H3K27ac in CD14+ monocytes. 
Summing of ChIP-seq reads overlapping the SNP in the heterozygous HeLa cell line shows 
that only the intact motif binds AP-1 TFs, Jun and Fos. d, Bar graph shows the fraction of 
PICS SNPs (black) versus random SNPs from the same locus (white) that create or disrupt 
one of the significantly enriched motifs, any Selex motif, or any conserved K-mer. Error 
bars indicate standard deviation from 1000 iterations using locus-matched control SNPs.
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Figure 6. Functional Effects of Disease Variants on Gene Expression
a, Pie charts show the fraction of PICS autoimmunity SNPs (left) or peripheral blood eQTLs 
(right) explained by the indicated genomic features. b, GWAS signal for MS risk at the 
IKZF3 locus. The minor allele of rs12946510 (red) is associated with both disease risk and 
eQTL effect (decreased IKZF3 expression), while the minor allele of rs907091 (blue) scored 
as eQTL only (increased IKZF3 expression). c, eQTL association signal for IKZF3 shown 
for the same regions as in b. d, H3K27ac, DNaseI and conservation signals, and selected TF 
binding intervals are shown in the vicinity of rs12946510, which occurs in a conserved site 
marked by H3K27ac in multiple cell types, including CD20+ B-cells, and bound by multiple 
TFs. The C/T variation at this SNP does not disrupt any clearly defined DNA motif, but 
coincides with a degenerate MEF2 motif.
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